Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals Inc. (GB:0QZU)
:0QZU
RESEARCH TOOLSreports
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
4.3Last Year’s EPS
-12.83Same Quarter Last Year
Moderate Buy
Based on 26 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: -7.23%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
Vertex Pharmaceuticals demonstrated strong revenue growth and successful product launches in the U.S., but faced challenges with ex-U.S. revenue decline and increased operating expenses. The pipeline is advancing well with multiple programs in pivotal development, although the temporary pause in the VX-522 study represents a setback. Financial guidance for the year was raised, reflecting confidence in continued growth.Company Guidance
During the Vertex Pharmaceuticals First Quarter 2025 Earnings Call, the company reported solid financial performance and shared guidance for the year. Vertex achieved $2.77 billion in revenue for the first quarter, marking a 3% increase compared to Q1 2024. The company raised its full-year revenue guidance to a range of $11.85 billion to $12 billion, reflecting an approximate 8% growth at the midpoint. Vertex highlighted the successful U.S. launches of its cystic fibrosis medication, ALYFTREK, and the non-opioid pain treatment, JOURNAVX, which are expected to drive future revenue growth. They also reported progress on their gene-edited therapy, CASGEVY, for sickle cell disease and beta-thalassemia, with 90 patients having their first cell collections. Vertex is focused on advancing its pipeline, with pivotal development programs in diabetic peripheral neuropathy, type 1 diabetes, APOL-1 mediated kidney disease, and IgA nephropathy. The company continues to invest in R&D and commercial capabilities while maintaining a robust financial position with $11.4 billion in cash and investments.Revenue Growth
Vertex Pharmaceuticals reported $2.77 billion in revenue for Q1 2025, representing a 3% growth compared to Q1 2024. U.S. revenue grew by 9% year-over-year.
Product Launches and Approvals
Successful early launches of ALYFTREK and JOURNAVX, with positive feedback from patients and physicians. ALYFTREK approved in the U.S., U.K., and EU, with further approvals expected in Canada, Australia, and Switzerland.
Pipeline Advancements
Four programs in pivotal development are progressing, including Suzetrigine in diabetic peripheral neuropathy and Zimislecel in type 1 diabetes. Enrollment for several programs is on track to complete this year.
R&D and Commercial Expansion
Significant R&D progress with five programs in Phase III and ongoing diversification of the commercial portfolio.
CASGEVY Uptake
Approximately 90 patients have begun the treatment process with CASGEVY, and more than 65 authorized treatment centers have been established globally.
Financial Position
Vertex ended the quarter with $11.4 billion in cash and investments, and increased total revenue guidance for 2025 to $11.85 billion to $12 billion.
GB:0QZU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0QZU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 10, 2025 | $469.82 | $457.70 | -2.58% |
Nov 04, 2024 | $470.30 | $500.09 | +6.33% |
Aug 01, 2024 | $507.98 | $492.91 | -2.97% |
Feb 05, 2024 | $429.41 | $414.54 | -3.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vertex Pharmaceuticals Inc. (GB:0QZU) report earnings?
Vertex Pharmaceuticals Inc. (GB:0QZU) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Vertex Pharmaceuticals Inc. (GB:0QZU) earnings time?
Vertex Pharmaceuticals Inc. (GB:0QZU) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Vertex Pharmaceuticals Inc. stock?
The P/E ratio of Vertex Pharmaceuticals is N/A.
What is GB:0QZU EPS forecast?
GB:0QZU EPS forecast for the fiscal quarter 2025 (Q2) is 4.3.